Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature.

Biochemical and neuropathological studies of brains from individuals with Alzheimer disease (AD) provide clear evidence for an activation of inflammatory pathways, and long-term use of anti-inflammatory drugs is linked with reduced risk to develop the disease. As cause and effect relationships between inflammation and AD are being worked out, there is a realization that some components of this complex molecular and cellular machinery are most likely promoting pathological processes leading to AD, whereas other components serve to do the opposite. The challenge will be to find ways of fine tuning inflammation to delay, prevent, or treat AD.

[1]  Henry P. Treffers,et al.  Complement , 1966, The Yale Journal of Biology and Medicine.

[2]  W E Wilkinson,et al.  Alzheimer's disease: A study of epidemiological aspects , 1984, Annals of neurology.

[3]  L M Schuman,et al.  A case-control study of dementia of the Alzheimer type. , 1985, American journal of epidemiology.

[4]  Joseph Rogers,et al.  Immune system associated antigens expressed by cells of the human central nervous system , 1988, Neuroscience Letters.

[5]  S. Styren,et al.  Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease , 1988, Neurobiology of Aging.

[6]  D. Scott,et al.  Rheumatold Arthritis and Senile Dementia of the Alzhelmer's Type , 1989 .

[7]  P. Eikelenboom,et al.  Complement activation in amyloid plaques in Alzheimer’s dementia , 1988, Virchows Archiv. B, Cell pathology including molecular pathology.

[8]  D. Scott,et al.  Rheumatoid arthritis and senile dementia of the Alzheimer's type. , 1989, British journal of rheumatology.

[9]  P. Mcgeer,et al.  Complement-activated oligodendroglia: A new pathogenic entity identified by immunostaining with antibodies to human complement proteins C3d and C4d , 1990, Neuroscience Letters.

[10]  T. Koepsell,et al.  A case‐control study of Alzheimer's disease , 1990, Annals of neurology.

[11]  P. Mcgeer,et al.  Anti-inflammatory drugs and Alzheimer disease , 1990, The Lancet.

[12]  Anthony F Jorm,et al.  A case‐control study of Alzheimer's disease in Australia , 1990, Neurology.

[13]  V. ter meulen,et al.  Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Kurland,et al.  Rheumatoid arthritis and susceptibility to Alzheimer's disease , 1991, The Lancet.

[15]  P. Mcgeer,et al.  Prevalence of Dementia amongst Elderly Japanese with Leprosy: Apparent Effect of Chronic Drug Therapy , 1992 .

[16]  P. Mcgeer,et al.  Complement activation by beta-amyloid in Alzheimer disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Silverman,et al.  A case‐control study of Alzheimer's disease in China , 1992, Neurology.

[18]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[19]  KennethRockwood,et al.  The Canadian Study of Health and Aging* , 1994, Neurology.

[20]  C. Cotman,et al.  beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. , 1994, Journal of immunology.

[21]  W. McDonald,et al.  Inverse association of anti‐inflammatory treatments and Alzheimer's disease , 1994, Neurology.

[22]  P. Mcgeer,et al.  Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer's disease , 1994, Brain Research.

[23]  R. Myllykangas-Luosujärvi,et al.  Alzheimer's disease and rheumatoid arthritis. , 1994, British journal of rheumatology.

[24]  D. Birmingham,et al.  Complement receptors and regulatory proteins: immune adherence revisited and abuse by microorganisms , 1994, Clinical and experimental immunology.

[25]  M. Pericak-Vance,et al.  Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs , 1995, Neurobiology of Aging.

[26]  M. Folstein,et al.  Nonsteroidal anti-inflammatory drugs in Alzheimer's disease , 1995, Neurology.

[27]  D. Walker,et al.  Complement and cytokine gene expression in cultured microglia derived from postmortem human brains , 1995, Journal of neuroscience research.

[28]  A. Hofman,et al.  Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? , 1995, Neurology.

[29]  R. Mrak,et al.  Correlation of Astrocytic S100β Expression with Dystrophic Neurites in Amyloid Plaques of Alzheimer's Disease , 1996, Journal of neuropathology and experimental neurology.

[30]  Patrick L. McGeer,et al.  Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.

[31]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[32]  F. Maxfield,et al.  Slow Degradation of Aggregates of the Alzheimer’s Disease Amyloid β-Protein by Microglial Cells* , 1997, The Journal of Biological Chemistry.

[33]  L. Mucke,et al.  Amyloidogenic role of cytokine TGF-β1 in transgenic mice and in Alzheimer's disease , 1997, Nature.

[34]  B. Juurlink Response of Glial Cells to Ischemia: Roles of Reactive Oxygen Species and Glutathione , 1997, Neuroscience & Biobehavioral Reviews.

[35]  D. Walker,et al.  Expression of presenilin-1 and -2 mRNAs in rat and Alzheimer's disease brains , 1997, Brain Research.

[36]  L. Lue,et al.  Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease , 1997, Neurobiology of Aging.

[37]  T. Johns,et al.  Binding of complement component Clq to myelin oligodendrocyte glycoprotein: A novel mechanism for regulating CNS inflammation , 1997 .

[38]  J. Loike,et al.  Microglia, Scavenger Receptors, and the Pathogenesis of Alzheimer’s Disease , 1998, Neurobiology of Aging.

[39]  Pier Paolo Pandolfi,et al.  Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies , 1998, Nature Genetics.

[40]  A. Hoes,et al.  NSAIDs and incident Alzheimer’s disease. the Rotterdam study , 1998, Neurobiology of Aging.

[41]  E. Kokmen,et al.  Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. , 1998, Mayo Clinic proceedings.

[42]  T. Johns,et al.  Binding of complement component C1q to myelin oligodendrocyte glycoprotein: A novel mechanism for regulating CNS inflammation , 1998, Journal of Neuroimmunology.

[43]  N. Delanty,et al.  Risk of Alzheimer's disease and duration of NSAID use , 1998, Neurology.

[44]  M. Carroll,et al.  The role of complement and complement receptors in induction and regulation of immunity. , 1998, Annual review of immunology.

[45]  S. Paul,et al.  The NF-κB/Rel family of proteins mediates Aβ-induced neurotoxicity and glial activation , 1998 .

[46]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Mattson,et al.  Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. , 1999, Science.

[48]  P. Gasque,et al.  Differential expression of individual complement regulators in the brain and choroid plexus. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[49]  P. Mcgeer,et al.  Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs , 1999, Brain Research.

[50]  A. Tenner Membrane receptors for soluble defense collagens. , 1999, Current opinion in immunology.

[51]  P. Mcgeer,et al.  Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.

[52]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[53]  H J Koch,et al.  A randomized controlled trial of prednisone in Alzheimer’s disease , 2000, Neurology.

[54]  M. Emmerling,et al.  The role of complement in Alzheimer's disease pathology. , 2000, Biochimica et biophysica acta.

[55]  P. Mcgeer Cyclo-Oxygenase-2 Inhibitors , 2000, Drugs & aging.

[56]  M. Norton,et al.  Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists , 2000, Neurology.

[57]  P. Taylor,et al.  A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo , 2000, The Journal of experimental medicine.

[58]  Rena Li,et al.  Deficiency of Complement Defense Protein CD59 May Contribute to Neurodegeneration in Alzheimer's Disease , 2000, The Journal of Neuroscience.

[59]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[60]  W. Griffin,et al.  Overexpression of the Neuritotrophic Cytokine S100β Precedes the Appearance of Neuritic β‐Amyloid Plaques in APPV717F Mice , 2000 .

[61]  S. Paul,et al.  Overexpression of the neuritotrophic cytokine S100beta precedes the appearance of neuritic beta-amyloid plaques in APPV717F mice. , 2000, Journal of neurochemistry.

[62]  L. Waite,et al.  Anti-inflammatory drugs protect against Alzheimer disease at low doses. , 2000, Archives of neurology.

[63]  P. Gasque,et al.  Complement components of the innate immune system in health and disease in the CNS. , 2000, Immunopharmacology.

[64]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[65]  L. Mucke,et al.  TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice , 2001, Nature Medicine.

[66]  E. Topol,et al.  Risk of cardiovascular events associated with selective COX-2 inhibitors. , 2001, JAMA.

[67]  M. Goldberg,et al.  Amyloid-β Peptides Are Cytotoxic to Oligodendrocytes , 2001, The Journal of Neuroscience.

[68]  Virginia M. Y. Lee,et al.  Complement activation by neurofibrillary tangles in Alzheimer's disease , 2001, Neuroscience Letters.

[69]  H. Hampel,et al.  Inflammatory repertoire of Alzheimer's disease and nondemented elderly microglia in vitro , 2001, Glia.

[70]  D. Wilcock,et al.  Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice , 2001, Neurobiology of Aging.

[71]  D. Birmingham,et al.  CR1 and CR1‐like: the primate immune adherence receptors , 2001, Immunological reviews.

[72]  P. Worley,et al.  Age-Dependent Cognitive Deficits and Neuronal Apoptosis in Cyclooxygenase-2 Transgenic Mice , 2001, The Journal of Neuroscience.

[73]  L. Lue,et al.  Modeling microglial activation in Alzheimer’s disease with human postmortem microglial cultures , 2001, Neurobiology of Aging.

[74]  L. Lue,et al.  Gene expression profiling of amyloid beta peptide-stimulated human post-mortem brain microglia , 2001, Neurobiology of Aging.

[75]  E. Connolly,et al.  The Role of the Complement Cascade in Ischemia/Reperfusion Injury: Implications for Neuroprotection , 2001, Molecular medicine.

[76]  John D Lambris,et al.  Structure and biology of complement protein C3, a connecting link between innate and acquired immunity , 2001, Immunological reviews.

[77]  David J. Cummins,et al.  Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[78]  P. Rezaie,et al.  MESOGLIA & MICROGLIA – A Historical Review of the Concept of Mononuclear Phagocytes Within the Central Nervous System , 2002, Journal of the history of the neurosciences.

[79]  J. Berman,et al.  CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to beta-amyloid fibrils. , 2002, The American journal of pathology.

[80]  Tony Wyss-Coray,et al.  Inflammation in Neurodegenerative Disease—A Double-Edged Sword , 2002, Neuron.

[81]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[82]  C. Wolfson,et al.  A Case-Control Analysis of Nonsteroidal Anti-Inflammatory Drugs and Alzheimer’s Disease: Are They Protective? , 2002, Neuroepidemiology.

[83]  D. Miller,et al.  Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[84]  P. Zandi,et al.  Reduced incidence of AD with NSAID but not H2 receptor antagonists: The Cache County Study , 2002, Neurology.

[85]  G. Garden Microglia in human immunodeficiency virus‐associated neurodegeneration , 2002, Glia.

[86]  John D Lambris,et al.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[87]  J. Julien,et al.  Innate immunity: the missing link in neuroprotection and neurodegeneration? , 2002, Nature Reviews Neuroscience.

[88]  D. Basso,et al.  The Neuropathological and Behavioral Consequences of Intraspinal Microglial/Macrophage Activation , 2002, Journal of neuropathology and experimental neurology.

[89]  B. Winblad,et al.  Up-regulation of the inflammatory cytokines IFN-γ and IL-12 and down-regulation of IL-4 in cerebral cortex regions of APPSWE transgenic mice , 2002, Journal of Neuroimmunology.

[90]  R. Hébert,et al.  Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. , 2002, American journal of epidemiology.

[91]  D. Teplow,et al.  Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. , 2002, Gene expression.

[92]  K. Moore,et al.  CD36 Mediates the Innate Host Response to β-Amyloid , 2003, The Journal of experimental medicine.

[93]  T. Wyss-Coray,et al.  Adult mouse astrocytes degrade amyloid-β in vitro and in situ , 2003, Nature Medicine.

[94]  J. Ryu,et al.  Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. , 2003, Neuroreport.

[95]  C. Brosnan,et al.  Cytokines: Powerful Regulators of Glial Cell Activation , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[96]  K. Davis,et al.  Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.

[97]  J. Ting,et al.  Functional Genomic Analysis of Remyelination Reveals Importance of Inflammation in Oligodendrocyte Regeneration , 2003, The Journal of Neuroscience.

[98]  Pamela L. Follett,et al.  Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[99]  G. Mcclearn,et al.  Does aspirin protect against Alzheimer's dementia? A study in a Swedish population-based sample aged ≥80 years , 2003, European Journal of Clinical Pharmacology.

[100]  P. Mcgeer,et al.  Expression of complement messenger RNAs and proteins by human oligodendroglial cells , 2003, Glia.

[101]  V. Perry,et al.  Systemic infection, interleukin 1β, and cognitive decline in Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[102]  M. D'Andrea Evidence linking neuronal cell death to autoimmunity in Alzheimer’s disease , 2003, Brain Research.

[103]  M. D'Andrea,et al.  Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.

[104]  Andrea Russo,et al.  Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[105]  A. Iwasaki,et al.  Toll-like receptor control of the adaptive immune responses , 2004, Nature Immunology.

[106]  C. Kawas,et al.  Neuronal localization of C1q in preclinical Alzheimer's disease , 2004, Neurobiology of Disease.

[107]  P. Mcgeer,et al.  Expression of the histocompatibility glycoprotein HLA-DR in neurological disease , 2004, Acta Neuropathologica.

[108]  Rena Li,et al.  CCAAT/enhancer binding protein δ (C/EBPδ) expression and elevation in Alzheimer’s disease , 2004, Neurobiology of Aging.

[109]  Xi Chen,et al.  RAGE potentiates Aβ‐induced perturbation of neuronal function in transgenic mice , 2004, The EMBO journal.

[110]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[111]  T. Town,et al.  Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.

[112]  W. Markesbery,et al.  Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[113]  J. Julien,et al.  Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis , 2004, The Journal of Neuroscience.

[114]  Jun Zhou,et al.  Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease , 2004, The Journal of Neuroscience.

[115]  C. Lines,et al.  Rofecoxib , 2004, Neurology.

[116]  Xianlin Han,et al.  Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase–ceramide pathway , 2004, The Journal of Cell Biology.

[117]  P. Mcgeer,et al.  Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs , 2004, Journal of Neuroinflammation.

[118]  J. Mitchell,et al.  Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[119]  P. Eikelenboom,et al.  Immunoglobulins and complement factors in senile plaques , 1982, Acta Neuropathologica.

[120]  Polly Matzinger,et al.  Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses , 2004, Nature Reviews Immunology.

[121]  Rena Li,et al.  CCAAT/enhancer binding protein delta (C/EBPdelta) expression and elevation in Alzheimer's disease. , 2004, Neurobiology of aging.

[122]  P. Gasque Complement: a unique innate immune sensor for danger signals. , 2004, Molecular immunology.

[123]  M. Duchen,et al.  β-Amyloid Peptides Induce Mitochondrial Dysfunction and Oxidative Stress in Astrocytes and Death of Neurons through Activation of NADPH Oxidase , 2004, The Journal of Neuroscience.

[124]  B. Winblad,et al.  Aspirin, NSAIDs, Risk of Dementia, and Influence of the Apolipoprotein E Epsilon 4 Allele in an Elderly Population , 2004, Neuroepidemiology.

[125]  K. Ishii,et al.  The LPS receptor (CD14) links innate immunity with Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[126]  Jill A. White,et al.  Differential effects of oligomeric and fibrillar amyloid-β1–42 on astrocyte-mediated inflammation , 2005, Neurobiology of Disease.

[127]  L. Thal,et al.  A Randomized, Double-Blind, Study of Rofecoxib in Patients with Mild Cognitive Impairment , 2005, Neuropsychopharmacology.

[128]  W. Gan,et al.  ATP mediates rapid microglial response to local brain injury in vivo , 2005, Nature Neuroscience.

[129]  Pritam Das,et al.  Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production , 2005, Nature Medicine.

[130]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[131]  H. Neumann,et al.  LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. , 2005, Brain : a journal of neurology.

[132]  K. Krause,et al.  Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases , 2005, Brain Research Reviews.

[133]  R. von Bernhardi,et al.  Oligodendrocytes damage in Alzheimer's disease: beta amyloid toxicity and inflammation. , 2005, Biological research.

[134]  E. Blalock,et al.  Calcineurin Triggers Reactive/Inflammatory Processes in Astrocytes and Is Upregulated in Aging and Alzheimer's Models , 2005, The Journal of Neuroscience.

[135]  F. Helmchen,et al.  Resting Microglial Cells Are Highly Dynamic Surveillants of Brain Parenchyma in Vivo , 2005, Science.

[136]  A. Stromberg,et al.  Harnessing the power of gene microarrays for the study of brain aging and Alzheimer's disease: Statistical reliability and functional correlation , 2005, Ageing Research Reviews.

[137]  W. Blakemore,et al.  Inflammation stimulates remyelination in areas of chronic demyelination. , 2005, Brain : a journal of neurology.

[138]  V. Perry,et al.  Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and Increase Neuronal Death during Chronic Neurodegeneration , 2005, The Journal of Neuroscience.

[139]  L. Lue,et al.  Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases , 2005, Journal of neuroscience research.

[140]  L. V. Van Eldik,et al.  Enhanced susceptibility of S‐100B transgenic mice to neuroinflammation and neuronal dysfunction induced by intracerebroventricular infusion of human β‐amyloid , 2005, Glia.

[141]  Z. Janka,et al.  Gene expression profile analysis of lymphocytes from Alzheimer's patients , 2005, Psychiatric genetics.

[142]  James L. Buescher,et al.  Overexpression of monocyte chemotactic protein-1/ CCL2 in β-amyloid precursor protein transgenic mice show accelerated diffuse β-amyloid deposition , 2005 .

[143]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[144]  P. Moynagh The interleukin‐1 signalling pathway in astrocytes: a key contributor to inflammation in the brain , 2005, Journal of anatomy.

[145]  Ling Li,et al.  Role of toll-like receptor signalling in Abeta uptake and clearance. , 2006, Brain : a journal of neurology.

[146]  A. Savonenko,et al.  Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer’s disease in a sex-dimorphic pattern , 2006, Neuroscience.

[147]  Chao Zhao,et al.  Inflammation stimulates myelination by transplanted oligodendrocyte precursor cells , 2006, Glia.

[148]  S. Lovestone,et al.  Proteome-based plasma biomarkers for Alzheimer's disease. , 2006, Brain : a journal of neurology.

[149]  Rena Li,et al.  Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes , 2006, Neurobiology of Aging.

[150]  B. Martin,et al.  Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.

[151]  D. Holtzman,et al.  Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism , 2006, The Journal of Neuroscience.

[152]  L. Mucke,et al.  Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. , 2006, The Journal of clinical investigation.

[153]  B. Botterman,et al.  Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.

[154]  E. Sigurdsson,et al.  Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology , 2006, Journal of neuropathology and experimental neurology.

[155]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[156]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[157]  E. Sheta,et al.  2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases , 2006, Expert review of proteomics.

[158]  J. Rogers,et al.  Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. , 2006, Journal of Alzheimer's disease : JAD.

[159]  Hyman M. Schipper,et al.  Transcriptional profiling of Alzheimer blood mononuclear cells by microarray , 2007, Neurobiology of Aging.

[160]  Michael M. Halassa,et al.  Synaptic Islands Defined by the Territory of a Single Astrocyte , 2007, The Journal of Neuroscience.

[161]  L. McCullough,et al.  Function of COX-2 and Prostaglandins in Neurological Disease , 2007, Journal of Molecular Neuroscience.

[162]  X. Chen,et al.  RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. , 2007, Current molecular medicine.

[163]  A. Bessis,et al.  Microglial control of neuronal death and synaptic properties , 2007, Glia.

[164]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[165]  B. Winblad,et al.  Decreased Fractalkine and Increased IP-10 Expression in Aged Brain of APPswe Transgenic Mice , 2008, Neurochemical Research.

[166]  R. Green,et al.  Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial , 2007, Neurology.

[167]  John D. Lambris,et al.  The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.

[168]  W. Robberecht,et al.  Microglia in amyotrophic lateral sclerosis. , 2007, Acta neurologica Belgica.

[169]  P. Rezaie,et al.  The origin and cell lineage of microglia—New concepts , 2007, Brain Research Reviews.

[170]  S. Lockett,et al.  Induction of the Formyl Peptide Receptor 2 in Microglia by IFN-γ and Synergy with CD40 Ligand12 , 2007, The Journal of Immunology.

[171]  G. Martino,et al.  Multifaceted aspects of inflammation in multiple sclerosis: The role of microglia , 2007, Journal of Neuroimmunology.

[172]  P. Zandi,et al.  NSAIDs for the chemoprevention of Alzheimer's disease. , 2007, Sub-cellular biochemistry.

[173]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[174]  M. O’Banion,et al.  Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.

[175]  Rajagopal N. Aravalli,et al.  Toll-like Receptors in Defense and Damage of the Central Nervous System , 2007, Journal of Neuroimmune Pharmacology.

[176]  R. Ransohoff The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro. , 2007, Journal of neuroimmunology.

[177]  D. Menon,et al.  The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro , 2007, Journal of Neuroimmunology.

[178]  J. Rogers,et al.  Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? , 2007, International review of neurobiology.

[179]  Holger Heine,et al.  Role of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease , 2007, Cellular Physiology and Biochemistry.

[180]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[181]  O. Hurtado,et al.  Toll-Like Receptor 4 Is Involved in Brain Damage and Inflammation After Experimental Stroke , 2007, Circulation.

[182]  F. Maxfield,et al.  Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. , 2007, Molecular biology of the cell.

[183]  J. Ringman,et al.  Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin , 2007, Proceedings of the National Academy of Sciences.

[184]  Rena Li,et al.  Deletion of tumor necrosis factor death receptor inhibits amyloid β generation and prevents learning and memory deficits in Alzheimer's mice , 2007, The Journal of Cell Biology.

[185]  S. Lockett,et al.  Induction of the formyl peptide receptor 2 in microglia by IFN-gamma and synergy with CD40 ligand. , 2007, Journal of immunology.

[186]  C. Ferrari,et al.  Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease , 2008, Brain : a journal of neurology.

[187]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[188]  H. Brodaty,et al.  Faculty Opinions recommendation of NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type. , 2008 .

[189]  N. Grigoriadis,et al.  Increased expression of the γ‐secretase components presenilin‐1 and nicastrin in activated astrocytes and microglia following traumatic brain injury , 2008, Glia.

[190]  A. Luster,et al.  Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. , 2008, Trends in pharmacological sciences.

[191]  Makoto Sawada,et al.  Imaging of Peripheral Benzodiazepine Receptor Expression as Biomarkers of Detrimental versus Beneficial Glial Responses in Mouse Models of Alzheimer's and Other CNS Pathologies , 2008, The Journal of Neuroscience.

[192]  G. Landreth,et al.  The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. , 2008, CNS drugs.

[193]  F. Haiss,et al.  Dynamics of the Microglial/Amyloid Interaction Indicate a Role in Plaque Maintenance , 2008, The Journal of Neuroscience.

[194]  F. Maxfield,et al.  Degradation of fibrillar forms of Alzheimer's amyloid β-peptide by macrophages , 2008, Neurobiology of Aging.

[195]  Martin Rossor,et al.  Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study , 2008, Neurobiology of Disease.

[196]  V. Echeverria,et al.  Transcription factor Sp1 dysregulation in Alzheimer's disease , 2008, Journal of neuroscience research.

[197]  Hong-Duck Kim,et al.  Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease , 2008, Journal of Neuroinflammation.

[198]  V. Perry,et al.  Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration , 2008, Neurobiology of Disease.

[199]  D. Holtzman,et al.  Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease , 2008, Nature.

[200]  C. Bogdan Mechanisms and consequences of persistence of intracellular pathogens: leishmaniasis as an example , 2008, Cellular microbiology.

[201]  K. L. Richard,et al.  Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid β1–42 and Delay the Cognitive Decline in a Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[202]  T. Pufe,et al.  Involvement of formyl-peptide-receptor-like-1 and phospholipase D in the internalization and signal transduction of amyloid beta 1-42 in glial cells , 2008, Neuroscience.

[203]  D. Holtzman,et al.  Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice , 2008, The Journal of Neuroscience.

[204]  G. Landreth,et al.  The Role of Peroxisome Proliferator-Activated Receptor-γ PPARγ) in Alzheimer’s Disease , 2012 .

[205]  D. Bennett,et al.  Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology , 2008, Neurology.

[206]  C. Lemere,et al.  Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.

[207]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[208]  M. Goldberg,et al.  Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration , 2008, The Journal of Neuroscience.

[209]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[210]  C. Cao,et al.  Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice , 2009, Neuroscience.

[211]  M. Sofroniew,et al.  Astrocytes: biology and pathology , 2009, Acta Neuropathologica.

[212]  Monique Breteler,et al.  Identifying Early Markers of Alzheimer's Disease using Quantitative Multiplex Proteomic Immunoassay Panels , 2009, Annals of the New York Academy of Sciences.

[213]  H. Abdul,et al.  Cognitive Decline in Alzheimer's Disease Is Associated with Selective Changes in Calcineurin/NFAT Signaling , 2009, The Journal of Neuroscience.

[214]  R. Nelson,et al.  The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer's disease. , 2009, Current opinion in investigational drugs.

[215]  C. Combs Inflammation and Microglia Actions in Alzheimer’s Disease , 2009, Journal of Neuroimmune Pharmacology.

[216]  J. Nabekura,et al.  Resting Microglia Directly Monitor the Functional State of Synapses In Vivo and Determine the Fate of Ischemic Terminals , 2009, The Journal of Neuroscience.

[217]  Julie Price,et al.  Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. , 2009, Archives of neurology.

[218]  G. van Dijk,et al.  Inflammation and NF-kappaB in Alzheimer's disease and diabetes. , 2009, Journal of Alzheimer's disease : JAD.

[219]  P. Magistretti,et al.  The role of astroglia in neuroprotection , 2009, Dialogues in clinical neuroscience.

[220]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[221]  G. Landreth,et al.  Toll-like receptors in Alzheimer's disease. , 2009, Current topics in microbiology and immunology.

[222]  M. Mattson,et al.  Involvement of Fc Receptors in Disorders of the Central Nervous System , 2010, NeuroMolecular Medicine.

[223]  A. Dolga,et al.  Inflammation and NF-κB in Alzheimer’s Disease and Diabetes , 2009 .

[224]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[225]  S. Haneuse,et al.  Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort , 2009, Neurology.

[226]  J. Calderó,et al.  Development of microglia in the chick embryo spinal cord: Implications in the regulation of motoneuronal survival and death , 2009, Journal of neuroscience research.

[227]  W. Seaman,et al.  A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia , 2009, Journal of neurochemistry.

[228]  Yan Wang,et al.  Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice , 2009, The Journal of Neuroscience.

[229]  Vahram Haroutunian,et al.  Gain in Brain Immunity in the Oldest-Old Differentiates Cognitively Normal from Demented Individuals , 2009, PloS one.

[230]  C. Colton Heterogeneity of Microglial Activation in the Innate Immune Response in the Brain , 2009, Journal of Neuroimmune Pharmacology.

[231]  C. Heizmann,et al.  RAGE Does Not Affect Amyloid Pathology in Transgenic ArcAβ Mice , 2010, Neurodegenerative Diseases.

[232]  W. Streit,et al.  Life and Death of Microglia , 2009, Journal of Neuroimmune Pharmacology.

[233]  Jose Julio Rodriguez,et al.  Astroglia in dementia and Alzheimer's disease , 2009, Cell Death and Differentiation.

[234]  G. Landreth,et al.  CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation , 2009, The Journal of Neuroscience.

[235]  A. Kirkwood,et al.  Impaired cognition, sensorimotor gating, and hippocampal long-term depression in mice lacking the prostaglandin E2 EP2 receptor , 2009, Experimental Neurology.

[236]  P. Pasqualetti,et al.  A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease , 2009, Aging clinical and experimental research.

[237]  L. Lue,et al.  Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: A potential mechanism leading to chronic inflammation , 2009, Experimental Neurology.

[238]  J. Relton,et al.  Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[239]  T. Montine,et al.  The Prostaglandin E2 E-Prostanoid 4 Receptor Exerts Anti-Inflammatory Effects in Brain Innate Immunity , 2010, The Journal of Immunology.

[240]  G. Landreth,et al.  Microglia and inflammation in Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.

[241]  G. Halliday,et al.  Focal demyelination in Alzheimer’s disease and transgenic mouse models , 2010, Acta Neuropathologica.

[242]  Brent D. Cameron,et al.  Inflammation, microglia, and alzheimer's disease , 2010, Neurobiology of Disease.

[243]  K. Lunetta,et al.  Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. , 2010, Archives of neurology.

[244]  Susan M Resnick,et al.  Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. , 2010, Archives of general psychiatry.

[245]  G. Landreth,et al.  The role of microglia in amyloid clearance from the AD brain , 2010, Journal of Neural Transmission.

[246]  Christopher L. MacDonald,et al.  Amyloid β-peptide directly induces spontaneous calcium transients, delayed intercellular calcium waves and gliosis in rat cortical astrocytes , 2009, ASN neuro.

[247]  A. Tenner,et al.  C1q enhances microglial clearance of apoptotic neurons and neuronal blebs, and modulates subsequent inflammatory cytokine production , 2010, Journal of neurochemistry.

[248]  D. Dickson,et al.  Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[249]  S. Nam,et al.  Inflammation and Alzheimer’s disease , 2010, Archives of pharmacal research.

[250]  Murray Grossman,et al.  Novel CSF biomarkers for Alzheimer’s disease and mild cognitive impairment , 2010, Acta Neuropathologica.

[251]  P. Zandi,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010, CNS & neurological disorders drug targets.

[252]  S. C.A.,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010 .

[253]  Murray Grossman,et al.  Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease , 2010, Acta Neuropathologica.

[254]  C. Colton,et al.  Assessing activation states in microglia. , 2010, CNS & neurological disorders drug targets.

[255]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[256]  Thomas W. Mühleisen,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease , 2013, Nature Genetics.

[257]  A. Lbert,et al.  Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease , 2022 .